Literature DB >> 11277581

N100 evoked potential latency variation and startle in schizophrenia.

K A Young1, M Smith, T Rawls, D B Elliott, I S Russell, P B Hicks.   

Abstract

The contribution of evoked potential (EP) latency jitter, a measure of CNS temporal variability, on startle and EP gating defects in schizophrenic subjects has not been characterized. The amplitude of the N100/P200 EP complex (peak to trough) derived using a time-locked averaging procedure, N100 EP latency jitter derived from single trial analysis, acoustic startle response and clinical symptoms were measured in 51 schizophrenic subjects. N100 latency jitter was inversely correlated with N100/P200 EP amplitude in both cross-sectional and longitudinal analysis. Subjects with elevated EP gating ratios (>0.5) had similar latency jitter values for initial (S1) and test (S2) stimuli, while subjects with a low gating ratio (0-0.5) had a lower level of S1 latency jitter. Temporal variability thus plays a significant and complex role in previously reported sensory gating deficits in schizophrenic subjects.

Entities:  

Mesh:

Year:  2001        PMID: 11277581     DOI: 10.1097/00001756-200103260-00031

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

1.  Auditory evoked potential variability in healthy and schizophrenia subjects.

Authors:  Ben H Jansen; Lingli Hu; Nash N Boutros
Journal:  Clin Neurophysiol       Date:  2010-04-02       Impact factor: 3.708

2.  Test-Retest Reliability of Electroencephalographic Measures of Performance Monitoring in Children and Adults.

Authors:  Mei-Heng Lin; Patricia L Davies; Jaclyn Stephens; William J Gavin
Journal:  Dev Neuropsychol       Date:  2020-10-20       Impact factor: 2.253

3.  Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients.

Authors:  Nash N Boutros; Anke Brockhaus-Dumke; Klevest Gjini; Andrei Vedeniapin; Mohamad Elfakhani; Scott Burroughs; Matcheri Keshavan
Journal:  Schizophr Res       Date:  2009-06-12       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.